CRNX Share Price | Crinetics Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: How big is Crinetics Pharmaceuticals, Inc.?

Market Cap: As of Jun 18, Crinetics Pharmaceuticals, Inc. has a market capitalization of 2,890.03 million, classifying it as a Small Cap company.Recent Quarterly Performance: For the latest four quarters, Crinetics Pharmaceuticals, Inc. reported net sales of 0.36 million and a net profit of -328.25 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,324.81 million and total assets of 1,726.13 million.

Q: What does Crinetics Pharmaceuticals, Inc. do?

Overview: Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -97 Million (Quarterly Results - Mar 2025) Market cap: USD 2,890.03 Million (Small Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.01 Return on Equity: -26.18% Price to Book: 2.30Contact Details: Address: 10222 Barnes Canyon Rd Bldg 2, SAN DIEGO CA: 92121-2711 Tel: 1 858 4506464 Fax: 1 302 6365454 Website: https://www.crinetics.com/

Q: Who are in the management team of Crinetics Pharmaceuticals, Inc.?

As of March 2022, the management team of Crinetics Pharmaceuticals, Inc. includes the following individuals:- Dr. Wendall Wierenga, who serves as the Independent Chairman of the Board.- Dr. R. Scott Struthers, who is the President, Chief Executive Officer, and a Director.- Dr. Camille Bedrosian, who is an Independent Director.- Mr. Matthew Fust, who is also an Independent Director.- Dr. Stephen Kaldor, another Independent Director.- Mr. Weston Nichols, who serves as an Independent Director.- Ms. Stephanie Okey, who is an Independent Director.In summary, the management team consists of a mix of independent directors and executive leadership, with Dr. R. Scott Struthers as the CEO.

Q: Is Crinetics Pharmaceuticals, Inc. overvalued or undervalued?

As of 7 August 2025, the valuation grade for Crinetics Pharmaceuticals, Inc. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 2.47, an EV to EBITDA of -4.88, and a negative ROE of -26.18%. In comparison to its peers, Crinetics shows a significantly lower EV to EBITDA ratio than PTC Therapeutics, Inc. at 3.1714 and Ultragenyx Pharmaceutical, Inc. at -7.2361, further highlighting its relative weakness in valuation. Additionally, while Crinetics has seen a 5.19% return over the past week, it has underperformed on a year-to-date basis with a -30.61% return compared to the S&P 500's 12.22%, reinforcing the notion that the stock may be overvalued in the current market environment.

Q: Is Crinetics Pharmaceuticals, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Crinetics Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish. The daily moving averages indicate a bullish stance. However, the monthly Bollinger Bands and KST show bearish signals, and the Dow Theory indicates a mildly bullish trend on the weekly timeframe with no trend on the monthly. In terms of performance, the stock has underperformed the S&P 500 year-to-date and over the past year, with returns of -19.83% and -30.22%, respectively, compared to the S&P 500's 15.47% and 16.90%. However, over the longer term, the stock has significantly outperformed the benchmark with a 3-year return of 141.26% versus 78.85% for the S&P 500. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and moving averages.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.11 M

Shareholding (Sep 2025)

FII

14.98%

Held by 127 FIIs

DII

22.81%

Held by 67 DIIs

Promoter

7.34%

How big is Crinetics Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Crinetics Pharmaceuticals, Inc. has a market capitalization of $2.89 billion, with net sales of $0.36 million and a net profit of -$328.25 million over the latest four quarters. The company reported shareholder's funds of $1.32 billion and total assets of $1.73 billion as of Dec 24.

View full answer

What does Crinetics Pharmaceuticals, Inc. do?

22-Jun-2025

Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing treatments for specialty endocrine diseases and related tumors. As of March 2025, it has a market cap of approximately $2.89 billion, with no net sales and a net loss of $97 million.

View full answer

Who are in the management team of Crinetics Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, Crinetics Pharmaceuticals, Inc.'s management team includes Dr. R. Scott Struthers as CEO, along with several independent directors, including Dr. Wendall Wierenga as Chairman.

View full answer

Is Crinetics Pharmaceuticals, Inc. overvalued or undervalued?

20-Sep-2025

As of August 7, 2025, Crinetics Pharmaceuticals, Inc. is considered risky and overvalued, with a Price to Book Value of 2.47, a negative EV to EBITDA of -4.88, and a year-to-date return of -30.61%, significantly underperforming compared to its peers and the S&P 500.

View full answer

Is Crinetics Pharmaceuticals, Inc. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Crinetics Pharmaceuticals, Inc. shows a mildly bullish trend with a bullish weekly MACD and moving averages, despite underperforming the S&P 500 year-to-date and over the past year, while significantly outperforming it over the last three years.

View full answer

Compare Crinetics Pharmaceuticals, Inc. with Similar Stocks

IDEAYA Biosciences, Inc.Vericel Corp.PTC Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Operating profit has grown by an annual rate -234.52% of over the last 5 years

The company has declared negative results for the last 25 consecutive quarters

Risky - Negative EBITDA

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 5,218 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.01

Return on Equity

-39.46%

Price to Book

4.87

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Sep 2025)

Net Profit:

-130 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

19.02%

6 Months

77.32%

1 Year

28.75%

2 Years

20.65%

3 Years

134.76%

4 Years

154.19%

5 Years

173.94%

Crinetics Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

19.04%

EBIT Growth (5y)

-234.52%

EBIT to Interest (avg)

-198.84

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.47

EV to EBIT

-4.84

EV to EBITDA

-4.88

EV to Capital Employed

-132.79

EV to Sales

1824.64

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-26.18%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 73 Schemes (54.87%)

Foreign Institutions

Held by 127 Foreign Institutions (14.98%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -69.40% vs -33.57% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-141.60",
          "val2": "-87.00",
          "chgp": "-62.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-130.10",
          "val2": "-76.80",
          "chgp": "-69.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-997,104.90%",
          "val2": "0.00%",
          "chgp": "-99,710.49%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -75.00% vs -14.89% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -39.11% vs -30.87% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.00",
          "val2": "4.00",
          "chgp": "-75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-336.10",
          "val2": "-221.50",
          "chgp": "-51.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-298.40",
          "val2": "-214.50",
          "chgp": "-39.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-326,134.70%",
          "val2": "-55,471.70%",
          "chgp": "-27,066.30%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.10

0.00

Operating Profit (PBDIT) excl Other Income

-141.60

-87.00

-62.76%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-130.10

-76.80

-69.40%

Operating Profit Margin (Excl OI)

-997,104.90%

0.00%

-99,710.49%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -69.40% vs -33.57% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

1.00

4.00

-75.00%

Operating Profit (PBDIT) excl Other Income

-336.10

-221.50

-51.74%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-298.40

-214.50

-39.11%

Operating Profit Margin (Excl OI)

-326,134.70%

-55,471.70%

-27,066.30%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -75.00% vs -14.89% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -39.11% vs -30.87% in Dec 2023

All Annual Results

Company CV

About Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.

Company Coordinates

Company Details

10222 Barnes Canyon Rd Bldg 2 , SAN DIEGO CA : 92121-2711

Tel: 1 858 4506464

https://www.crinetics.com/

Registrar Details